Business Wire

Enero Announces the Appointment of Heather Kernahan as Global Chief Executive Officer of Hotwire

Share

Enero Group (ASX:EGG) has today announced the appointment of Heather Kernahan as Global Chief Executive Officer of Hotwire, the Group’s leading global technology communications consultancy. The appointment will see Kernahan report to Brent Scrimshaw, Enero Group CEO, effective 1 July 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005467/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Brent Scrimshaw, Enero Group CEO; Heather Kernahan, Hotwire Global CEO; Barbara Bates, Senior Advisor, Enero Group. (Photo: Business Wire)

Barbara Bates, who has successfully led Hotwire for the past five years, will move into a newly created senior advisory role at Enero. Bates will help facilitate Enero Group’s M&A activities in North America and will continue to report to Brent Scrimshaw.

“I would like to thank Barbara for her leadership and drive in Hotwire being the successful, global technology communications consultancy that it is today. She has been an innovative, respected and transformational leader across nearly three decades in the global communications industry. I am delighted she will remain in the Group.

“This change provides an excellent opportunity for Heather Kernahan to lead the next phase of growth for Hotwire. Heather has demonstrated incredible leadership in tackling the challenges and opportunities of a rapidly-growing business in Hotwire USA. Heather has the skills, experience and appetite for growth and her appointment demonstrates the deep bench strength of the Hotwire leadership team. I am confident she will continue to drive the business’ momentum and push Hotwire to even greater heights,” said Brent Scrimshaw.

Commenting on her appointment, Heather Kernahan said: “There is no more exciting industry to be in than technology and I’m thrilled to lead the Hotwire team as we continue to grow. We have ambitious plans to bring more value to our fast growth and global tech clients, who are looking for an alternative to the big multinational agencies. Barbara has led a culture, team and business that is sought after by the largest tech companies in the world and I’m honoured to now lead this organisation. With 20 years behind us, we feel that we’re just getting started.”

Barbara Bates said: “I’ve had the privilege to work with so many amazing people during my time at Hotwire, and I’m exceptionally proud of what we’ve managed to create together. Hotwire is already one of the world’s most highly-regarded tech communications businesses and with Heather’s leadership, it has never been better positioned to grow further. I’m excited to stay connected to the Enero Group and I look forward to continue building on the Group’s strong momentum and ambition.”

Heather Kernahan joined Hotwire from Eastwick Communications, as president of Hotwire North America and Australia, after its acquisition in 2016 by Enero Group. In 2019, she was named Hotwire CEO of North America. Under her leadership the agency has experienced record growth. With over 20 years of industry experience, Kernahan has held senior marketing and executive leadership roles at fast growth and global technology organisations including Autodesk, Enphase Energy and Alias. Under her leadership, Hotwire has developed partnerships with technology companies including: Adobe, Facebook, McAfee, Commvault, NetApp and Pinterest. As a global tech expert and business leader she has been named one of 2020 SF Business Times’ 100 Most Influential Women and is the Board Chair of The PR Council. Kernahan holds an MBA in Sustainable Enterprise from Dominican University of California.

This announcement comes as Hotwire continues to expand the team while delivering outstanding business results and following the successful acquisition of McDonald Butler Associates in London last month. In the past year, Hotwire has continued its 20 years of industry leadership, being named 2020 Global Technology Agency of the Year by PRovoke Media, Best Places to Work in PR by PRWeek for two years in a row and recently recognised as one of the Best Companies to Work for in the UK by the Sunday Times. Current clients include Accenture, Adobe, AWS, Citrix, Dell Technologies, Deloitte, Delphix, DXC Technology, eBay, GoPro, Honeywell, IBM, McAfee, Pegasystems and PWC.

About Enero:

Headquartered in Sydney, Australia, Enero Group is a boutique network of marketing and communications businesses listed on the ASX (Australian Stock Exchange) that includes creative agency BMF, PR and integrated communications agencies Hotwire and CPR, strategic data consultancies The Leading Edge and The Digital Edge, digital agency Orchard and programmatic marketing specialist OB Media. www.enero.com.

About Hotwire

Hotwire is the global technology communication consultancy. Founded in 2000, we operate a worldwide network of wholly owned offices and partners serving a range of clients from scale ups to established multi-nationals. We unleash the possibilities of innovative technology through integrated communications that ignite curiosity, spark action and fuel success. We do this using our proprietary methodology which is underpinned by robust insight and strategy, purposeful creative, integrated planning and a core emphasis on measurement and evaluation. www.hotwireglobal.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Lu Borges
Group Communications Director
d. +61 2 8985 7210
m. +61 422 755 492
lu.borges@enero.com

Kelsey Quickstad
Hotwire
Kelsey.quickstad@hotwireglobal.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion Healthcare presents the first real-world data for Truxima ® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 17:45:00 CEST | Press release

Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® ▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 09:01:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 09:00:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an

Alluzience ® , the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 11:53:00 CEST | Press release

Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As

Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 10:15:00 CEST | Press release

The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,

Luxembourg’s Supercomputer MeluXina is Operational11.6.2021 09:18:00 CEST | Press release

Luxembourg’s high performance computer MeluXina was officially launched on June 7 putting the country on the global map of computer super powers. MeluXina is capable of executing more than 10 Petaflops, the equivalent of 10 million billion calculations per second, which will rank it among the world’s top 50 supercomputers. The petascale computer is powered by green energy and is part-funded under the European High Performance Computing Joint Undertaking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005115/en/ Minister of State Xavier Bettel; His Royal Highness Henri, Grand Duke of Luxembourg; Minister of the Economy Franz Fayot; EuroHPC Joint Undertaking Executive Director Anders Jensen (Photo: Business Wire) In a series of 8 high-performance computers in the EU, MeluXina joins Vega, another petascale supercomputer located in Slovenia, as the first EuroHPC machines to go live. Its innovative modular architecture allo

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting11.6.2021 09:05:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics (Nasdaq:CRSP) today announced new data on 22 patients,with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment. CTX001 is being investigated in two ongoing Phase 1/2 clinical trials as a potential one-time therapy for patients suffering from transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). In total, more than 40 patients have been dosed across both studies to date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005069/en/ All 15 patients with TDT, including six who have the beta zero/beta zero or other severe genotypes, were transfusion-free at last follow-up, and all seven patients with severe SCD were free of vaso-occlusive crises (VOCs) from CTX001 infu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom